Lung Cancer Research Foundation & ALK Positive Announce New Research Partnership

The Lung Cancer Research Foundation (LCRF) and the ALK Positive Inc. (ALK Positive) have expanded its current research partnership to fund $2 million in ALK-positive related lung cancer projects over three years. The aim of this research is to advance high-impact research focused upon transforming care and improving outcomes for consumers with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). This funding mechanism will grant awards to selected projects; applications will be subject to a rigorous review by ALK Positive's Research Review Panel and LCRF's Scientific Advisory Board.

Anaplastic lymphoma kinase (ALK) rearrangements . . .